Inhibrx Biosciences secured a $150 million loan agreement with Oxford Finance, with $100 million funded initially and $50 million available upon request, maturing in 2030 and bearing interest at 5.61% plus SOFR or 4.34%. The agreement includes warrants for 140,741 shares at $14.21 each and imposes various covenants and events of default.